Cambridge Cognition's CANTAB platform selected for major brain health study
Why we think this is good
The RNS announcement highlights a positive development for Cambridge Cognition, with its CANTAB platform being selected as the core cognitive assessment tool for a major global brain health study. This validates the company's technology and represents a significant market opportunity, without any indication of negative financial or operational impacts. The news appears to be a positive update for the company's business.
Key Points
- CANTAB platform selected for Intuition Brain Health study, one of the world's largest brain health studies
- Study enrolled 23,004 participants across the US, sponsored by Biogen and conducted with Apple
- Selection of CANTAB validates its ability to deliver reliable digital cognitive measurements at scale
- Represents a significant market opportunity for Cambridge Cognition's cognitive assessment platform
Summary
Cambridge Cognition Holdings Plc, a neuroscience technology company, announced that its CANTAB platform was selected as the core cognitive assessment tool for the Intuition Brain Health study, one of the world's largest brain health studies. The study, sponsored by Biogen and conducted in collaboration with Apple, enrolled 23,004 participants across the US.
The RNS highlights that the selection of CANTAB validates the platform's proven ability to deliver reliable digital cognitive measurements in remote, large-scale settings, and reinforces Cambridge Cognition's leadership in digital brain health assessments. This represents a significant market opportunity for the company's cognitive assessment platform.